| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Rhodes Jason P78 | Director | Sell | 267,760 | $21.09 | $5,646,496.80 | -1.2% | - | - | |
| Jun 24, 2026 | ROIV Roivant Sciences Ltd. | Venker Eric | President &Immunovant CEO | Sell | 200,000 | $33.16 | $6,631,267.64 | -5.8% | - | - | |
| Jun 24, 2026 | IBRX Immunitybio, Inc. | Simon Barry J.79 | Director | Sell | 25,000 | $7.88 | $196,907.50 | -0.9% | - | - | |
| Jun 24, 2026 | CAPR Capricor Therapeutics, Inc. | Bergmann Anthony | Chief Financial Officer | Sell | 900 | $30.00 | $27,000.00 | -3.9% | - | - | |
| Jun 24, 2026 | CAPR Capricor Therapeutics, Inc. | Krasney Karen | EVP, General Counsel | Sell | 900 | $30.00 | $27,000.00 | -1.5% | - | - | |
| Jun 24, 2026 | RCUS Arcus Biosciences, Inc. | Jaen Juan C.75 | President | Sell | 31,431 | $27.92 | $877,501.25 | -0.9% | - | - | |
| Jun 24, 2026 | OTLC Oncotelic Therapeutics, Inc. | Trieu Vuong | Chairman And CEO | Buy | 255,000 | $0.05 | $11,475.00 | - | - | - | |
| Jun 24, 2026 | KRRO Korro Bio, Inc. | Formela Jean Francois70 | Director | Sell | 171,405 | $14.34 | $2,458,582.35 | -4.0% | - | - | |
| Jun 24, 2026 | BBIO Bridgebio Pharma, Inc. | Cook Jennifer E.60 | Director | Sell | 39,363 | $69.92 | $2,752,269.72 | -70.1% | - | - | |
| Jun 23, 2026 | ADTX Aditxt, Inc. | Takeover Time 2026 LLC | 10% Owner | Sell | 3,420,439 | $0.02 | $68,408.78 | -100% | - | - | |
| Jun 23, 2026 | CYTK Cytokinetics, Incorporated | Malik Fady Ibraham55 | EVP Research &Development | Sell | 3,500 | $79.51 | $278,285.00 | -2.2% | - | - | |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc. | Fairmount Funds Management LLC73 | Director | Sell | 4,684,781 | $85.31 | $399,658,667.11 | -100% | - | - | |
| Jun 23, 2026 | BBIO Bridgebio Pharma, Inc. | Valantine Hannah53 | Director | Sell | 5,004 | $68.25 | $341,523.72 | -19.5% | - | - | |
| Jun 23, 2026 | BCDA Biocardia, Inc. | Stertzer Simon H | Director | Buy | 109,200 | $0.95 | $103,584.00 | +59.2% | - | - | |
| Jun 22, 2026 | ORKA Oruka Therapeutics, Inc. | Agarwal Arjun | Senior Vice President, Finance | Sell | 1,587 | $80.95 | $128,468.24 | -4.8% | - | - | |
| Jun 22, 2026 | IRON Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Chief Operating Officer | Sell | 9,700 | $72.66 | $704,795.21 | -15.2% | - | - | |
| Jun 22, 2026 | SYRE Spyre Therapeutics, Inc. | Henderson Michael Thomas58 | Director | Sell | 20,000 | $100.00 | $2,000,000.00 | -22.6% | - | - | |
| Jun 22, 2026 | KARD Kardigan, Inc. | Hrtg Gpe, LLC | 10% Owner | Buy | 3,125,000 | $16.00 | $50,000,000.00 | +26.6% | - | - | |
| Jun 22, 2026 | VSTM Verastem, Inc. | Calkins Daniel63 | Chief Financial Officer | Sell | 4,089 | $4.18 | $17,089.17 | -1.7% | - | - | |
| Jun 22, 2026 | EVMN Evommune, Inc. | Pena Luis C. | President &CEO | Sell | 7,438 | $22.71 | $168,916.98 | -1.2% | - | - | |
| Jun 22, 2026 | EVMN Evommune, Inc. | Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell | 1,488 | $22.50 | $33,480.00 | -3.1% | - | - | |
| Jun 22, 2026 | URGN Urogen Pharma Ltd. | Schoenberg Mark60 | Chief Medical Officer | Sell | 10,000 | $35.01 | $350,100.00 | -7.2% | - | - | |
| Jun 22, 2026 | APGE Apogee Therapeutics, Inc. | Dambkowski Carl48 | Chief Medical Officer | Sell | 26,400 | $132.60 | $3,500,640.00 | -12.8% | - | - | |
| Jun 22, 2026 | VSTM Verastem, Inc. | Paterson Dan65 | President And CEO | Sell | 20,871 | $4.18 | $87,240.78 | -3.4% | - | - | |
| Jun 22, 2026 | EVMN Evommune, Inc. | Drew Janice Suzann | Chief Of Dev. Operations | Sell | 20,000 | $22.63 | $452,600.00 | -22.8% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.